Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
6(100.0%)
6Total
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06894693Phase 1Not Yet Recruiting

A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies

Role: lead

NCT06340490Phase 1Not Yet Recruiting

A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)

Role: lead

NCT06316076Phase 1Recruiting

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

Role: collaborator

NCT06314828Phase 1Not Yet Recruiting

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

Role: lead

NCT05858814Phase 1Recruiting

RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT

Role: lead

NCT05471323Phase 1Unknown

Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML

Role: lead

All 6 trials loaded